To define the functional impact of TGF-β and GITR pathway modulation on anti-glioma immune reactivity, we exposed splenocytes to SD208, one of two GITR agonists, or the combination of both, and assessed their lytic activity against glioma cells in co-culture assays. Here, TGFB1 is linked to glioma.